Endocrine Pharmacology — MCQs

Endocrine Pharmacology Indian Medical PG Practice Questions and MCQs

Question 501: GnRH agonist is used in all of the following EXCEPT?

A. Delaying puberty in individuals with precocious puberty
B. Endometriosis
C. Hypoestrogenism (Correct Answer)
D. Congenital adrenal hyperplasia

Explanation: The correct answer is **C. Hypoestrogenism**. **Mechanism of Action:** GnRH agonists (e.g., Leuprolide, Goserelin, Nafarelin) act on the pituitary gland. While an acute dose causes a "flare" of gonadotropins, **continuous/chronic administration** leads to the downregulation and desensitization of GnRH receptors [2]. This results in a state of **hypogonadotropic hypogonadism**, effectively lowering levels of estrogen and testosterone [2]. Therefore, GnRH agonists **cause** hypoestrogenism rather than treat it. **Analysis of Options:** * **A. Precocious Puberty:** Continuous GnRH agonists suppress the premature activation of the hypothalamic-pituitary-gonadal axis, delaying the onset of puberty and preventing premature epiphyseal closure [2]. * **B. Endometriosis:** These drugs create a "pseudomenopausal" state. By inducing hypoestrogenism, they cause the ectopic endometrial tissue to atrophy, providing symptomatic relief [1]. * **D. Congenital Adrenal Hyperplasia (CAH):** While not first-line, GnRH agonists are used as an adjunct in children with CAH who develop **secondary (central) precocious puberty** due to advanced bone age and early maturation of the axis. **Clinical Pearls for NEET-PG:** * **Pulsatile administration** of GnRH is used to treat **infertility** (stimulates FSH/LH) [2]. * **Continuous administration** is used for "medical castration" in **Prostate Cancer**, Endometriosis, and Uterine Fibroids [1]. * **Side Effects:** Hot flashes, decreased bone mineral density (osteoporosis), and vaginal dryness (all due to the induced hypoestrogenic state). * **Add-back therapy:** Low-dose estrogen/progestin is often given alongside GnRH agonists in endometriosis to prevent bone loss without losing the therapeutic effect.

Question 502: Galactorrhea may be associated with the use of all the following drugs except?

A. Methyldopa
B. Tricyclic antidepressants
C. Pyridoxine (Correct Answer)
D. Phenothiazine

Explanation: ### Explanation The physiological regulation of prolactin is primarily under the **inhibitory control of Dopamine** (Prolactin Inhibitory Factor) via D2 receptors in the anterior pituitary. Any drug that decreases dopamine levels or blocks its receptors will lead to hyperprolactinemia, resulting in **galactorrhea**. **Why Pyridoxine is the correct answer:** **Pyridoxine (Vitamin B6)** acts as a cofactor for the enzyme *L-amino acid decarboxylase*, which converts L-Dopa to Dopamine. By increasing peripheral dopamine synthesis, pyridoxine actually **suppresses prolactin secretion**. Historically, high doses of pyridoxine were used to treat lactation; therefore, it prevents rather than causes galactorrhea. **Analysis of Incorrect Options:** * **Methyldopa (Option A):** It is a centrally acting antihypertensive that acts as a "false neurotransmitter." It decreases central dopamine levels, leading to increased prolactin release. * **Tricyclic Antidepressants (Option B):** TCAs (like Amitriptyline) can cause galactorrhea by inhibiting dopamine activity or through mild serotonergic stimulation of prolactin. * **Phenothiazines (Option D):** These are typical antipsychotics (e.g., Chlorpromazine) that act as potent **D2 receptor antagonists** in the tuberoinfundibular pathway, making them a very common cause of drug-induced galactorrhea. **High-Yield Clinical Pearls for NEET-PG:** 1. **Metoclopramide and Domperidone** (anti-emetics) are frequent culprits of galactorrhea due to D2 blockade. 2. **Reserpine** causes galactorrhea by depleting dopamine stores. 3. **Bromocriptine and Cabergoline** (Dopamine agonists) are the drugs of choice for treating hyperprolactinemia/prolactinomas. 4. **Pyridoxine Interaction:** It reduces the efficacy of Levodopa in Parkinson’s disease by increasing its peripheral metabolism (unless a DOPA-decarboxylase inhibitor like Carbidopa is added).

Question 503: Bromocriptine is known to:

A. Inhibit prolactin release (Correct Answer)
B. Inhibit adrenalin synthesis
C. Inhibit insulin synthesis
D. Inhibit thyroid synthesis

Explanation: **Explanation:** **Bromocriptine** is a potent **Dopamine D2 receptor agonist** derived from ergot alkaloids. 1. **Why Option A is Correct:** In the anterior pituitary, dopamine acts as the primary **Prolactin Inhibiting Hormone (PIH)**. By stimulating D2 receptors on lactotrophs, Bromocriptine mimics the action of endogenous dopamine, leading to a significant reduction in the synthesis and secretion of prolactin. This makes it a first-line treatment for hyperprolactinemia and prolactinomas. 2. **Why Other Options are Incorrect:** * **Option B (Adrenalin):** Adrenalin synthesis occurs in the adrenal medulla via the catecholamine pathway (Tyrosine → DOPA → Dopamine → NE → Adrenalin). Bromocriptine does not inhibit the enzymes (like PNMT) involved in this process. * **Option C (Insulin):** Insulin synthesis is regulated by glucose levels and ionic shifts in pancreatic beta cells; it is not inhibited by dopamine agonists. * **Option D (Thyroid):** Thyroid hormone synthesis is regulated by TSH and iodine organification. While dopamine can mildly suppress TSH, Bromocriptine is not used to inhibit thyroid synthesis. **High-Yield Clinical Pearls for NEET-PG:** * **Other Uses:** Apart from hyperprolactinemia, it is used in **Parkinson’s disease** (due to D2 stimulation in the striatum), **Acromegaly** (paradoxically decreases GH in these patients), and **Type 2 Diabetes Mellitus** (Quick-release formulation). * **Side Effects:** Nausea and vomiting (due to CTZ stimulation), postural hypotension, and digital vasospasm. * **Drug of Choice:** While Bromocriptine is classic, **Cabergoline** is now preferred for hyperprolactinemia due to its higher efficacy, longer half-life (twice-weekly dosing), and better tolerability.

Question 504: Troglitazone is the drug used in the treatment of which condition?

A. Petit mal epilepsy
B. Type 2 diabetes mellitus (Correct Answer)
C. Hyperlipidemia
D. Osteoporosis

Explanation: **Explanation:** **Correct Answer: B. Type 2 diabetes mellitus** **Mechanism of Action:** Troglitazone belongs to the **Thiazolidinedione (TZD)** class of oral hypoglycemic agents. These drugs act as selective agonists for the **Peroxisome Proliferator-Activated Receptor-gamma (PPAR-γ)**, a nuclear receptor primarily located in adipose tissue, muscle, and liver. Activation of PPAR-γ regulates the transcription of genes involved in glucose and lipid metabolism, leading to increased expression of glucose transporters (GLUT-4) and decreased insulin resistance. Essentially, TZDs are "insulin sensitizers." **Analysis of Incorrect Options:** * **A. Petit mal epilepsy:** Also known as Absence seizures, this is typically treated with Ethosuximide or Sodium Valproate. Troglitazone has no anticonvulsant properties. * **C. Hyperlipidemia:** While TZDs do affect lipid metabolism (often increasing HDL), they are not primary treatments for hyperlipidemia. Statins or Fibrates (which act on PPAR-α) are the drugs of choice here. * **D. Osteoporosis:** Interestingly, TZDs are actually associated with an *increased* risk of bone fractures and decreased bone mineral density, making them contraindicated or used with caution in patients with osteoporosis. **High-Yield Clinical Pearls for NEET-PG:** * **Hepatotoxicity:** Troglitazone was the first TZD but was **withdrawn** from the market worldwide due to severe idiosyncratic hepatotoxicity. * **Current TZDs:** Pioglitazone and Rosiglitazone are the currently used drugs in this class. * **Side Effects:** Common adverse effects of TZDs include weight gain, fluid retention (edema), and precipitation of congestive heart failure (CHF). * **Monitoring:** Due to the history of Troglitazone, periodic liver function tests (LFTs) are recommended for patients on any TZD therapy.

Question 505: Which of the following mechanisms best explains the contraceptive effect of birth control pills that contain both synthetic estrogen and progestin?

A. Direct inhibition of oocyte maturation
B. Inhibition of ovulation (Correct Answer)
C. Production of uterine secretions that are toxic to developing embryos
D. Impairment of implantation hyperplastic changes of the endometrium

Explanation: **Explanation:** The primary mechanism of action of Combined Oral Contraceptive Pills (COCPs) is the **inhibition of ovulation** through negative feedback on the hypothalamic-pituitary-ovarian axis. 1. **Why B is correct:** * **Estrogen component:** Suppresses the release of **FSH** (Follicle Stimulating Hormone) from the anterior pituitary, which prevents the development of a dominant follicle. * **Progestin component:** Suppresses the release of **LH** (Luteinizing Hormone). By preventing the mid-cycle LH surge, ovulation is inhibited. * Additionally, progestins thicken the cervical mucus (preventing sperm penetration) and alter the endometrium to make it unfavorable for implantation. 2. **Why other options are incorrect:** * **Option A:** COCPs do not directly affect the oocyte's internal maturation process; they prevent the hormonal signal required for the follicle to rupture. * **Option C:** COCPs do not produce "toxic" secretions. While they alter the chemical composition of the mucus, it is not embryotoxic. * **Option D:** While COCPs cause endometrial thinning (making it less receptive), they do not cause "hyperplastic" changes. In fact, they are protective against endometrial hyperplasia and cancer. **High-Yield Clinical Pearls for NEET-PG:** * **Most common side effect:** Breakthrough bleeding (especially with low-dose pills). * **Serious Risk:** Venous Thromboembolism (VTE), especially in smokers >35 years (due to the estrogen component increasing clotting factors II, VII, IX, and X). * **Non-contraceptive benefits:** Reduced risk of **Ovarian and Endometrial cancers**, reduced incidence of PID, and improvement in dysmenorrhea. * **Drug Interaction:** Enzyme inducers like **Rifampicin** decrease the efficacy of OCPs by increasing their metabolism.

Question 506: Which of the following is a GLP-1 agonist?

A. Pramlintide
B. Exenatide (Correct Answer)
C. Sitagliptin
D. None of the above

Explanation: **Explanation:** The correct answer is **Exenatide (Option B)**. **1. Mechanism of Action (The Correct Answer):** Exenatide is a synthetic analog of **Glucagon-Like Peptide-1 (GLP-1)**, an incretin hormone. It acts as a GLP-1 receptor agonist, stimulating glucose-dependent insulin secretion, inhibiting glucagon release, slowing gastric emptying, and increasing satiety. It is resistant to degradation by the enzyme DPP-4, giving it a longer half-life than endogenous GLP-1. **2. Analysis of Incorrect Options:** * **A. Pramlintide:** This is a synthetic analog of **Amylin**. It is used as an adjunct to insulin in both Type 1 and Type 2 Diabetes. It suppresses glucagon and slows gastric emptying but does not act on GLP-1 receptors. * **C. Sitagliptin:** This is a **DPP-4 inhibitor** (Gliptin). Instead of mimicking GLP-1, it prevents the breakdown of endogenous GLP-1 and GIP. It is an oral medication, whereas GLP-1 agonists are typically injectables. **3. High-Yield Clinical Pearls for NEET-PG:** * **Weight Effect:** GLP-1 agonists (Exenatide, Liraglutide, Semaglutide) are associated with significant **weight loss**, making them ideal for obese diabetic patients. * **Source:** Exenatide was originally isolated from the saliva of the **Gila monster** (*Heloderma suspectum*). * **Side Effects:** The most common side effects are GI-related (nausea/vomiting). A rare but serious association is **acute pancreatitis**. * **Cardiovascular Benefit:** Liraglutide and Semaglutide have proven benefits in reducing major adverse cardiovascular events (MACE).

Question 507: What is the drug of choice for treating diabetes in an obese patient?

A. Glipizide
B. Insulin
C. Tolbutamide
D. Metformin (Correct Answer)

Explanation: **Explanation:** **Metformin** is the first-line drug of choice for Type 2 Diabetes Mellitus (T2DM), particularly in obese patients. The primary mechanism of action is the activation of **AMP-activated protein kinase (AMPK)**, which leads to decreased hepatic gluconeogenesis and improved peripheral insulin sensitivity. **Why Metformin is the correct choice:** 1. **Weight Neutrality/Loss:** Unlike most other antidiabetics, Metformin is associated with weight stability or modest weight loss, making it ideal for obese patients. 2. **Cardiovascular Benefits:** It is the only oral hypoglycemic agent proven to reduce macrovascular complications and mortality in T2DM. 3. **Safety:** It has a negligible risk of hypoglycemia because it does not stimulate insulin secretion (it is an "euglycemic" agent). **Analysis of Incorrect Options:** * **Glipizide & Tolbutamide (Sulfonylureas):** These drugs act by stimulating insulin release from pancreatic beta cells. A major side effect of hyperinsulinemia is **weight gain**, which is counterproductive in obese patients. They also carry a high risk of hypoglycemia. * **Insulin:** While highly effective, insulin therapy is typically associated with significant **weight gain** and the risk of severe hypoglycemia. It is generally reserved for patients who fail oral therapy or have specific contraindications. **High-Yield Clinical Pearls for NEET-PG:** * **Side Effects:** The most common side effects are GI upset (diarrhea, abdominal cramps). The most serious, though rare, is **Lactic Acidosis**. * **Contraindications:** Avoid in patients with renal impairment (eGFR <30 mL/min) due to the risk of lactic acidosis. * **Vitamin Deficiency:** Long-term use can lead to **Vitamin B12 deficiency**. * **PCOS:** Metformin is also used to induce ovulation in obese women with Polycystic Ovary Syndrome.

Question 508: Which of the following statements is true about tamoxifen?

A. Selective estrogen receptor downregulator
B. Selective estrogen receptor modulator (Correct Answer)
C. Selective tissue estrogen activator regulator
D. Estrogen antagonist

Explanation: **Explanation:** **Tamoxifen** is the prototype **Selective Estrogen Receptor Modulator (SERM)** [2]. The core concept behind SERMs is their **tissue-specific action**: they act as competitive antagonists in some tissues while acting as partial agonists in others [2]. * **Why Option B is Correct:** Tamoxifen binds to estrogen receptors (ER), but its effect depends on the co-regulators present in the specific tissue [2]. It acts as an **antagonist in the breast** (inhibiting tumor growth) [1] but as an **agonist in the bone** (preventing bone loss) [3] and the **uterus** (stimulating endometrial proliferation) [2]. **Analysis of Incorrect Options:** * **Option A (SERD):** Selective Estrogen Receptor Downregulators (e.g., **Fulvestrant** [1]) bind to and trigger the degradation of the estrogen receptor. Unlike SERMs, they lack agonist activity [2]. * **Option C (STEAR):** Selective Tissue Estrogen Activity Regulators (e.g., **Tibolone**) are synthetic steroids used in HRT that have estrogenic, progestogenic, and androgenic properties. * **Option D (Estrogen Antagonist):** While Tamoxifen is an antagonist in the breast, calling it a pure antagonist is incorrect because it possesses significant agonist activity in other tissues [2]. **High-Yield Clinical Pearls for NEET-PG:** 1. **Clinical Use:** Drug of choice for ER-positive breast cancer in both pre- and post-menopausal women [1]. 2. **Side Effects:** Increased risk of **Endometrial Carcinoma** (due to uterine agonism) and **Thromboembolism** (DVT/PE) [1]. 3. **Beneficial Side Effect:** It decreases LDL levels and prevents postmenopausal osteoporosis [3]. 4. **Raloxifene:** Another SERM that is an antagonist in both breast and uterus, thus it does **not** increase the risk of endometrial cancer [3].

Question 509: Which antihormonal substance is used to induce ovulation?

A. Mifepristone
B. Clomiphene citrate (Correct Answer)
C. Tamoxifen
D. Raloxifen

Explanation: **Explanation:** **Clomiphene citrate** is the correct answer because it is a **Selective Estrogen Receptor Modulator (SERM)** that acts as a competitive antagonist at estrogen receptors in the hypothalamus and anterior pituitary. By blocking the negative feedback of endogenous estrogen, it triggers an increase in the pulsatile secretion of **GnRH**, which subsequently increases **FSH and LH** levels. This "surge" stimulates follicular development and induces ovulation, making it a first-line treatment for ovulatory dysfunction (e.g., PCOS). **Analysis of Incorrect Options:** * **Mifepristone (A):** A potent **progesterone receptor antagonist** (and glucocorticoid antagonist). It is primarily used for medical termination of pregnancy (MTP) and cervical ripening, not for ovulation induction. * **Tamoxifen (C):** A SERM used primarily in the treatment and prophylaxis of **estrogen receptor-positive breast cancer**. While it can induce ovulation, it is not the standard clinical choice for this purpose compared to Clomiphene. * **Raloxifene (D):** A SERM used for the prevention and treatment of **postmenopausal osteoporosis**. It has estrogenic effects on bone but anti-estrogenic effects on the breast and uterus; it does not significantly stimulate the hypothalamic-pituitary axis for ovulation. **High-Yield Pearls for NEET-PG:** * **Mechanism:** Acts as a "pure" antagonist at the hypothalamus (blocks negative feedback). * **Side Effects:** Multiple pregnancies (twins), ovarian hyperstimulation syndrome (OHSS), and vasomotor flushes. * **Contraindications:** Liver disease and ovarian cysts. * **Alternative:** **Letrozole** (an Aromatase Inhibitor) is now often preferred over Clomiphene for ovulation induction in PCOS patients due to better live birth rates and lower risk of multiple gestations.

Question 510: Which of the following statements about Afrezza is incorrect?

A. Used for both Type I and Type II diabetes
B. Substitute for long-acting insulin (Correct Answer)
C. It is a rapid-acting insulin
D. Used as an inhaled insulin formulation with Technosphere technology

Explanation: ### Explanation **Afrezza** is a rapid-acting inhaled insulin formulation. Understanding its pharmacokinetics is crucial for identifying its clinical role. **1. Why Option B is the Correct (Incorrect Statement):** Afrezza is a **rapid-acting insulin** with an onset of action within 12–15 minutes and a short duration of approximately 180 minutes. Because it mimics the physiological "prandial" (mealtime) insulin spike, it **cannot substitute for long-acting (basal) insulin**. Patients with Type 1 Diabetes still require a long-acting injectable insulin (like Glargine or Degludec) to maintain basal glucose levels. **2. Analysis of Other Options:** * **Option A:** It is FDA-approved for both **Type 1 and Type 2 Diabetes Mellitus** to control mealtime glucose. * **Option C:** It is categorized as rapid-acting. Its peak action is reached faster than subcutaneous Lispro or Aspart. * **Option D:** It utilizes **Technosphere technology**, where insulin molecules are adsorbed onto fumaryl diketopiperazine (FDKP) microparticles. These particles are small enough to reach the alveoli for systemic absorption. **High-Yield Clinical Pearls for NEET-PG:** * **Contraindications:** Afrezza is strictly contraindicated in patients with chronic lung diseases like **Asthma or COPD** due to the risk of acute bronchospasm. * **Monitoring:** A baseline **Spirometry (FEV1)** is mandatory before initiation, at 6 months, and annually thereafter. * **Common Side Effect:** The most frequently reported adverse effect is a **dry cough**. * **Smokers:** It is not recommended in patients who smoke or have recently quit smoking (<6 months).

Practice by Chapter

Hypothalamic and Pituitary Hormones

Practice Questions

Thyroid Drugs and Antithyroid Agents

Practice Questions

Insulin and Oral Hypoglycemic Agents

Practice Questions

Adrenocorticosteroids

Practice Questions

Sex Hormones: Estrogens and Progestins

Practice Questions

Androgens and Anabolic Steroids

Practice Questions

Hormonal Contraceptives

Practice Questions

Drugs Affecting Calcium Metabolism

Practice Questions

Drugs for Osteoporosis

Practice Questions

Pharmacological Management of Obesity

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free